Clinical trials: Glomerulonephritis, Membranous
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab
Membranous nephropathy is a rare autoimmune kidney disease in which autoantibodies, most commonly anti-PLA2R1 antibodies, target podocyte antigens and may cause nephrotic syndrome.
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Nephrotic Syndrome
- Trial name
- TRANSCRIPT (NCT07811557)
- Testing
- Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Membranous Nephropathy
Obinutuzumab in Primary MN
Primary membranous nephropathy (MN) is an antibody-mediated autoimmune glomerular disease, that represents one of the most frequent causes of nephrotic syndrome in adults.
- Trial name
- ORION (NCT05050214)
- Testing
- Obinutuzumab
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Idiopathic Membranous Nephropathy
Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy
Idiopathic membranous nephropathy (IMN) is one of the common types of primary glomerular diseases and the most common cause of nephrotic syndrome in adults.
- Trial name
- NCT05782933
- Testing
- Rituximab, Modified Ponticelli regimen
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Beijing Friendship Hospital
Idiopathic Membranous Nephropathy
Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy
The purpose of this study is to determine whether treatment with long-acting synthetic adrenocorticotropic hormone is in the treatment of patients with idiopathic membranous nephropathy and high for renal failure.
- Trial name
- ACTHiMeN (NCT00694863)
- Testing
- tetracosactide hexacetaat
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Lupus Nephritis, Glomerulonephritis, Membranous
A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
This is a prospective randomized open-label pilot study to compare mycophenolate mofetil in combination with corticosteroid treatment and tacrolimus in combination with corticosteroid treatment in membranous lupus nephritis.
- Trial name
- NCT00404794
- Testing
- prednisolone and mycophenolate mofetil, prednisolone and tacrolimus
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hospital Authority, Hong Kong
Lupus Membranous Nephropathy
Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).
- Trial name
- NCT03285711
- Testing
- Filgotinib, Lanraplenib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Gilead Sciences
Membranous Nephropathy, Nephrotic Syndrome
Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy
This prospective observational study aims to evaluate predictors of disease progression in patients with primary membranous nephropathy and to assess the performance of a prognostic nomogram in predicting renal outcomes in the…
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome, Kidney Diseases
- Trial name
- NCT07785739
- Volunteers
- 128 people
- Sponsor
- Assiut University
Membranous Nephropathy
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
Membranous Nephropathy (MN) is an auto-immune kidney disease and a common cause of nephrotic syndrome. About 30% of MN patients progress to end-stage kidney disease (ESKD) while 30% undergo spontaneous remission.
- Trial name
- SOURIS (NCT02199145)
- Testing
- Blood and urine analysis
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Membranous Nephropathy
A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacokinetics(PK) ,pharmacodynamics（PD）and anti-drug antibodies（ADA） of MIL62 compared with cyclosporine in participants with primary membranous nephropathy (pMN).
- Trial name
- NCT05862233
- Testing
- MIL62, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Idiopathic Membranous Nephropathy
Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid
The purpose of this study is: To explore the potential role of Tripterygium wilfordii plus steroid in the treatment of membranous nephropathy. To investigate the safety and tolerability of Tripterygium wilfordii plus steroid
- Trial name
- NCT01161459
- Testing
- Tripterygium wilfordii, FK506
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhi-Hong Liu, M.D.
Idiopathic Membranous Nephropathy
Rivaroxaban in Idiopathic Membranous Nephropathy
Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN).
- Trial name
- NCT07404436
- Testing
- Rivaroxaban 10 MG, Warfarin Sodium
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Beijing Friendship Hospital
Primary Membranous Nephropathy
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
- Trial name
- NCT07289763
- Testing
- SHR-2173 injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Primary Membranous Nephropathy
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
- Trial name
- AUTUMN (NCT07157787)
- Testing
- ALXN1920
- Where
- 40 sites in United States, Argentina and 8 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Autoimmune Membranous Nephropathy
Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy
Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune system although the exact mechanism is not completely known.
- Trial name
- PRISM (NCT03255447)
- Testing
- Immunoadsorption
- Where
- 3 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust